Affordable Access

deepdyve-link
Publisher Website

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Authors
  • Kaushik, Amit1
  • Ammerman, Nicole C1
  • Martins, Olumide1
  • Parrish, Nicole M2
  • Nuermberger, Eric L3
  • 1 Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • 2 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • 3 Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA [email protected]
Type
Published Article
Journal
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Publication Date
Jun 01, 2019
Volume
63
Issue
6
Identifiers
DOI: 10.1128/AAC.00470-19
PMID: 30962331
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections. Copyright © 2019 American Society for Microbiology.

Report this publication

Statistics

Seen <100 times